{"id":"W2096246254","doi":"10.1056/nejmoa1310907","title":"Edoxaban versus Warfarin in Patients with Atrial Fibrillation","year":2013,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Atrial Fibrillation Management and Outcomes","field":"Medicine","cited_by":5126,"is_retracted":false,"has_abstract":true,"ca_institutions":"McMaster University; Women's College Hospital","funders":"Biosense Webster; St. Jude Medical; Eisai; Janssen Scientific Affairs; Daiichi Sankyo Europe; Sanofi; Bayer HealthCare; Medicines Company; Boston Scientific Corporation; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; AtriCure; Janssen Pharmaceuticals; Gilead Sciences; Pfizer","keywords":"Edoxaban; Atrial fibrillation; Warfarin; Medicine; Cardiology; Internal medicine; Rivaroxaban","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null}